After receiving standard full-course anti-TB therapy combined anti-tumor therapy with chemotherapy, vascular targeting, and PD-1 inhibitor, the patient achieved ideal efficacy with mild adverse reactions, which is worthy of clinical reference. This evidence concerns the gene PDCD1 and neoplasm.